
Virtonomy
Data driven clinical trials on virtual patients based on an ever-expanding database to reflect anatomical variability, demographic diversity and pathological conditions.
- B2B
- saas
- commission
- health
- health platform
- medical devices
- biotechnology
- artificial intelligence
- big data
- deep tech
- virtual reality
- computer vision
- biotechnology
- horizon europe
- dt and ls
- core ai
- ai applications
- immersive technologies
- eit ecosystem
- eit health
- ai drug discovery
- techbio
- digital pharma
- medical imaging
- techbio drug discovery
- headstart (eit health)
- medical research
- ai for medical imaging
- clinical trials
- digital twin
- medical education
- headstart 2020 (eit health)

USD | 2021 | 2022 | 2023 |
---|---|---|---|
Revenues | 0000 | 0000 | 0000 |
% growth | - | 15 % | 88 % |
EBITDA | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Virtonomy is a pioneering startup that focuses on revolutionizing the medical device development industry through the use of digital patient twins. Essentially, the company creates virtual models of patients, known as "vPatients," which allow medical device developers to conduct development and testing in a simulated environment. This innovative approach significantly accelerates the development process, reduces risks, cuts down expenses, and eases the regulatory burden typically associated with bringing medical devices to market.
The primary clients of Virtonomy are medical device developers and manufacturers. These clients benefit from the company's ability to simulate the performance of their devices under various conditions, which might be challenging or impossible to replicate with human subjects. By leveraging computational modeling and simulation, Virtonomy helps these developers meet regulatory requirements more efficiently and cost-effectively.
Virtonomy operates in the medical device development market, a sector that is highly regulated and requires rigorous testing and validation before products can be approved for use. The company's business model revolves around providing virtual testing services and regulatory consulting. They offer workshops and expert guidance on how to integrate computational modeling into the regulatory process, aligning with new FDA guidelines and ASME standards.
Revenue is generated through service fees for virtual testing plans, consulting services, and specialized workshops. By offering these services, Virtonomy helps its clients shorten their time to market, which can translate into significant cost savings and faster access to revenue streams from new medical devices.
In summary, Virtonomy is a key player in the medical device development industry, providing innovative solutions that streamline the development and regulatory approval process through the use of digital patient twins.
Keywords: digital twins, medical devices, virtual testing, regulatory consulting, computational modeling, simulation, FDA guidelines, ASME standards, cost savings, accelerated development.